JP2019511554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511554A5 JP2019511554A5 JP2018554361A JP2018554361A JP2019511554A5 JP 2019511554 A5 JP2019511554 A5 JP 2019511554A5 JP 2018554361 A JP2018554361 A JP 2018554361A JP 2018554361 A JP2018554361 A JP 2018554361A JP 2019511554 A5 JP2019511554 A5 JP 2019511554A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- composition according
- inhibitor
- egfr tki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 claims 11
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 11
- 229940121647 egfr inhibitor Drugs 0.000 claims 9
- 108091000080 Phosphotransferase Proteins 0.000 claims 5
- 102000020233 phosphotransferase Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000035269 cancer or benign tumor Diseases 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 claims 2
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 claims 2
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- -1 tesebatinib Chemical compound 0.000 claims 2
- QKDCLUARMDUUKN-XMMPIXPASA-N 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide Chemical compound N1=C(O[C@H]2CN(CC2)C(=O)C=C)C(CC)=NC(C(N)=O)=C1NC(C=C1)=CC=C1N(CC1)CCC1N1CCN(C)CC1 QKDCLUARMDUUKN-XMMPIXPASA-N 0.000 claims 1
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 239000005461 Canertinib Substances 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- BTYYWOYVBXILOJ-UHFFFAOYSA-N N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide Chemical compound C12=CC(NC(=O)C#CC)=CC=C2N=CN=C1NC1=CC=CC(Br)=C1 BTYYWOYVBXILOJ-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- MXDSJQHFFDGFDK-CYBMUJFWSA-N [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2r)-2,4-dimethylpiperazine-1-carboxylate Chemical compound C=12C=C(OC(=O)N3[C@@H](CN(C)CC3)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F MXDSJQHFFDGFDK-CYBMUJFWSA-N 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 238000010256 biochemical assay Methods 0.000 claims 1
- 229950002826 canertinib Drugs 0.000 claims 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000000423 cell based assay Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims 1
- 229950002205 dacomitinib Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229950007440 icotinib Drugs 0.000 claims 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- BFSRTTWIPACGMI-UHFFFAOYSA-N n-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C=1C=C(NC=2N=C(NC=3C=C(NC(=O)C=C)C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1NC1CN(CCF)C1 BFSRTTWIPACGMI-UHFFFAOYSA-N 0.000 claims 1
- KJBZQIKLKWQVLL-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(7-methyl-7-azaspiro[3.5]nonan-2-yl)methoxy]quinazolin-6-yl]prop-2-enamide Chemical compound C1CN(C)CCC11CC(COC=2C(=CC3=C(NC=4C=C(Cl)C(F)=CC=4)N=CN=C3C=2)NC(=O)C=C)C1 KJBZQIKLKWQVLL-UHFFFAOYSA-N 0.000 claims 1
- ZAJXXUDARPGGOC-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C)(C)C#CC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C ZAJXXUDARPGGOC-UHFFFAOYSA-N 0.000 claims 1
- 229950009708 naquotinib Drugs 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229950000778 olmutinib Drugs 0.000 claims 1
- 229960003278 osimertinib Drugs 0.000 claims 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950006474 sapitinib Drugs 0.000 claims 1
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022126194A JP2022145800A (ja) | 2016-04-15 | 2022-08-08 | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323537P | 2016-04-15 | 2016-04-15 | |
| US62/323,537 | 2016-04-15 | ||
| PCT/US2017/027719 WO2017181075A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126194A Division JP2022145800A (ja) | 2016-04-15 | 2022-08-08 | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511554A JP2019511554A (ja) | 2019-04-25 |
| JP2019511554A5 true JP2019511554A5 (OSRAM) | 2020-06-11 |
| JP7123806B2 JP7123806B2 (ja) | 2022-08-23 |
Family
ID=60039950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554361A Active JP7123806B2 (ja) | 2016-04-15 | 2017-04-14 | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ |
| JP2022126194A Pending JP2022145800A (ja) | 2016-04-15 | 2022-08-08 | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126194A Pending JP2022145800A (ja) | 2016-04-15 | 2022-08-08 | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10322128B2 (OSRAM) |
| EP (1) | EP3442505A4 (OSRAM) |
| JP (2) | JP7123806B2 (OSRAM) |
| KR (2) | KR20230020565A (OSRAM) |
| CN (1) | CN109562176A (OSRAM) |
| AU (2) | AU2017248762A1 (OSRAM) |
| BR (1) | BR112018071031A2 (OSRAM) |
| CA (1) | CA3021021A1 (OSRAM) |
| IL (2) | IL262323B (OSRAM) |
| MX (2) | MX2018012511A (OSRAM) |
| WO (1) | WO2017181075A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017120349A1 (en) * | 2016-01-05 | 2017-07-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein |
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
| BR112018071023A2 (pt) | 2016-04-15 | 2019-02-05 | Felicitex Therapeutics Inc | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose |
| CA3168211A1 (en) | 2019-01-18 | 2020-07-23 | Voronoi Co., Ltd. | Pyrrolopyridine derivative and use thereof for preventing or treating protein kinase related disease |
| KR20200135743A (ko) * | 2019-05-22 | 2020-12-03 | 보로노이 주식회사 | 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2022265950A1 (en) * | 2021-06-15 | 2022-12-22 | Genentech, Inc. | Egfr inhibitor and perk activator in combination therapy and their use for treating cancer |
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| CN115947673B (zh) * | 2022-12-19 | 2024-03-15 | 湖南岳靶生物医药有限公司 | 一种化疗药物增敏剂、组合物及其应用 |
| CN116212030A (zh) * | 2023-03-03 | 2023-06-06 | 河南真实生物科技有限公司 | 包含阿兹夫定的抗肿瘤药物组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560004A1 (de) * | 2011-08-19 | 2013-02-20 | DST Diagnostische Systeme & Technologien GmbH | Neues PoC-Testsystem und Verfahren |
| PL2744797T3 (pl) * | 2011-08-19 | 2016-01-29 | Diaxonhit | Inhibitory dyrk1 i ich zastosowanie |
| US20150292032A1 (en) * | 2012-10-10 | 2015-10-15 | Felicitex Therapeutics, Inc. | Treatment of cancer by targeting quiescent cancer cells |
| CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| PE20170127A1 (es) | 2014-03-20 | 2017-03-30 | Samumed Llc | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| US20170304313A1 (en) * | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| CN108135871B (zh) * | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
| BR112018071023A2 (pt) | 2016-04-15 | 2019-02-05 | Felicitex Therapeutics Inc | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose |
-
2017
- 2017-04-14 CN CN201780037696.7A patent/CN109562176A/zh active Pending
- 2017-04-14 JP JP2018554361A patent/JP7123806B2/ja active Active
- 2017-04-14 MX MX2018012511A patent/MX2018012511A/es unknown
- 2017-04-14 CA CA3021021A patent/CA3021021A1/en active Pending
- 2017-04-14 EP EP17783286.2A patent/EP3442505A4/en not_active Withdrawn
- 2017-04-14 BR BR112018071031-8A patent/BR112018071031A2/pt not_active Application Discontinuation
- 2017-04-14 KR KR1020237002826A patent/KR20230020565A/ko not_active Ceased
- 2017-04-14 WO PCT/US2017/027719 patent/WO2017181075A1/en not_active Ceased
- 2017-04-14 US US15/488,116 patent/US10322128B2/en active Active
- 2017-04-14 KR KR1020187033052A patent/KR102494174B1/ko active Active
- 2017-04-14 AU AU2017248762A patent/AU2017248762A1/en not_active Abandoned
-
2018
- 2018-10-11 IL IL262323A patent/IL262323B/en unknown
- 2018-10-12 MX MX2023000549A patent/MX2023000549A/es unknown
-
2019
- 2019-06-17 US US16/442,973 patent/US11202779B2/en not_active Expired - Fee Related
-
2021
- 2021-12-08 IL IL288777A patent/IL288777A/en unknown
- 2021-12-20 US US17/556,869 patent/US20220110940A1/en not_active Abandoned
-
2022
- 2022-08-08 JP JP2022126194A patent/JP2022145800A/ja active Pending
-
2023
- 2023-01-27 AU AU2023200428A patent/AU2023200428A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022145800A5 (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた、新生物に罹患する対象を処置する方法 | |
| JP2019511553A5 (OSRAM) | ||
| MX2025002170A (es) | Inhibidores de kras g12c | |
| JP2021526133A5 (OSRAM) | ||
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MA45920B1 (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| JP2021510376A5 (OSRAM) | ||
| JP2015512943A5 (OSRAM) | ||
| SI2601177T1 (en) | N-acylsulfonamide apoptosis promoters | |
| JP2020529993A5 (OSRAM) | ||
| IL275762B2 (en) | History of PHENYL-SO2-NH-C(=O)-PHENYL-PIPERAZINE-CH2-1,2-CYCLOHEXANE-BICYCLO[1.1.1]PENTANE and spirit preparations containing them | |
| WO2025049814A2 (en) | Ribonucleotide reductase (rnr) compositions and methods of use | |
| EP4248988A3 (en) | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell | |
| MY199409A (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| MX2010002543A (es) | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. | |
| JP2017511311A5 (OSRAM) | ||
| CA3074017A1 (en) | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers | |
| MX418519B (es) | Inhibidores selectivos de jak1 | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| JP2020510032A5 (OSRAM) | ||
| JP2020514409A5 (OSRAM) | ||
| JP2008528671A5 (OSRAM) | ||
| MX2012002875A (es) | Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos. |